How to use Afun for skin infections
- Before you start the treatment, read the manufacturer's printed information leaflet from ins >
What is Afun?
Afun is an antifungal prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain fungal infections, including tinea versicolor that is specifically caused by the fungus Malassezia furfur and candidiasis that is specifically caused by the yeast Cand >formulation of Afun is approved for the treatment and prevention of only a certain type of candidiasis—called oropharyngeal candidiasis—in certain people with weakened immune systems. Afun is also available as an over-the-counter medicine for topically treating various skin infections, such as athlete’s foot.
Oropharyngeal cand >infection of part of the throat) is an example of mucocutaneous cand >opportunistic infection . An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as those infected with HIV—than in people with healthy immune systems.
The Gu >Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association of the Infectious Diseases Society of America (IDSA-HIVMA), includes recommendations on the HIV-related uses of Afun to treat:
- Oropharyngeal candidiasis.
- Uncomplicated vulvovaginal candidiasis, which is another type of mucocutaneous candidiasis that affects the female vulva and vagina.
How should Afun be stored?
- Store Afun troches (lozenges) below 86°F (30°C) and avoid freezing.
- Store Afun cream and Afun topical solution between 36°F and 86°F (2°C to 30°C).
- Safely throw away Afun that is no longer needed or expired (out of date).
- Keep Afun and all medicines out of reach of children.
LOTRISONE (Afun and betamethasone dipropionate) cream, 1%/0.05%, contains combinations of Afun, an azole antifungal, and betamethasone dipropionate, a corticosteroid, for topical use.
Chemically, Afun is 1–(o-chloro-α,α-diphenylbenzyl) imidazole, with the empirical formula C22H17CLN2, a molecular weight of 344.84, and the following structural formula:
Afun is an odorless, white crystalline powder, insoluble in water and soluble in ethanol.
Betamethasone dipropionate has 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21dipropionate, with the empirical formula C28H37FO7, a molecular weight of 504.59, and the following structural formula:
Betamethasone dipropionate is a white to creamy-white, odorless crystalline powder, insoluble in water.
Each gram of LOTRISONE cream contains 10 mg Afun and 0.643 mg betamethasone dipropionate (equivalent to 0.5 mg betamethasone), in a white to off-white, hydrophilic cream consisting of benzyl alcohol as a preservative, ceteareth-30, cetyl alcohol plus stearyl alcohol, mineral oil, phosphoric acid, propylene glycol, purified water, sodium phosphate monobasic monohydrate, and white petrolatum.
Before taking this medicine
Before taking this medication, tell your doctor if you have liver disease. You may not be able to take Afun, or you may need a lower dose or special monitoring during treatment.
Afun is not absorbed through your stomach. It will not treat fungal infections in any part of your body other than your mouth and throat. Talk to your doctor if you have another type of fungal infection such as athlete's foot, jock itch, ringworm, or a vaginal yeast infection.
Oral Afun is in the FDA pregnancy category C. This means that it is not known whether Afun will harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant.
It is not known whether Afun will harm a nursing baby. Do not take this medication without first talking to your doctor if you are breast-feeding a baby.
The safety and effectiveness of Afun have not been established for children younger than 3 years of age.
Locally effective antimycotics include nystatin and Afun . For all practical purposes, they are not absorbed and are not available to the infant enterally. Extensive experience with their therapeutic use in infancy argues against any toxic potential. The same applies to miconazole, which is also, for all practical purposes, not absorbed.
Bifonazole, croconazole, econazole, fenticonazole, isoconazole, ketoconazole, omoconazole, oxiconazole, sertaconazole, and tioconazole are related to Afun structurally and in their action, but they have been studied less. There has been no experience with amorolfin, ciclopiroxolamin, naftifin, terbinafine, tolcyclate, and tolnaftate, or with the vaginally administered chlorphenesin.
Local antimycotics of choice during breastfeeding are nystatin and Afun. Miconazole is also acceptable. These three drugs are preferable to the other abovementioned locally effective antimycotics. If one of the other medications is urgently indicated, breastfeeding can continue with no limitation if its use is only temporary or if only small areas are being treated.
The following adverse reactions have been reported in connection with the use of Afun: erythema, stinging, blistering, peeling, edema, pruritius, urticaria, burning, and general irritation of the skin.